small is powerfulⓇ
Nanoform works to improve the lives of patients globally by overcoming drug development and delivery challenges through our game-changing technologies and novel formulation capabilities. We have a dedicated, multi-disciplinary team with a combined experience of launching 100+ medicines.
Annual General Meeting 2025
The Annual General Meeting 2025 of Nanoform Finland Plc will be held on Tuesday 15 April 2025 at 10:00 a.m. (Finnish time) at Viikinkaari 4, Helsinki, Finland (meeting room 105, 1. floor).
Nanoform Partners
We are pleased to be working closely with key stakeholders in the pharma industry, including 10 of the world’s top 20 pharma companies in the sector.
Nanoform’s collaboration with TargTex
TargTex Ceo João Seixas discusses the value Nanoform’s CESS® technology delivered for TargTex’s drug candidate targeting glioblastoma.
Download our sustainability Ebook!
At Nanoform, we are proud to reflect our dedication to sustainability in our cutting-edge nanoparticle engineering processes. Discover how we are driving sustainability in the pharma industry in our Ebook.
A Globally Unique Capability for Nanoforming HPAPIs
Dr. David Rowe, Head of Manufacturing and Antonio da Silva, Chief of Business Operations discuss Nanoform’s capabilites in the HPAPI’s manufacturing space.
Our technologies
Small molecules
Our multi-patented Controlled Expansion of Supercritical Solutions (CESS®) technology enables the creation of API nanoparticles directly from solution. The process can be applied to most small molecules, with a high success rate.
Biologics
Our biological nanoforming technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. It’s effectiveness has been demonstrated on proteins in the 1-150 kDa range, and it is capable of engineering particle sizes to specific requirements.
Formulation
Our experienced formulation development team designs and develops flexible dosage forms of nanoformed drug substances to meet preclinical and clinical development as well as life-cycle needs. Our dosage forms cover oral, parenteral, ophthalmic and inhaled therapies and more.
GMP Manufacturing
We have GMP manufacturing capabilities for the manufacture of nanoformed clinical-grade API’s (Active Pharmaceutical Ingredients) for our customers and partners.
HIGH POTENCY CAPABILITIES
Our GMP facility is currently able to handle compounds with OEL of 1 ug/m3 and above. In H1 2023, we are expanding this offering for highly-potent compound manufacturing to handle API with OEL down to 30 ng/m3
LATEST PRESS RELEASES & NEWS
To read more of our latest news and see our recent articles and videos, visit our media centre
Harness the power of AI to discover if your molecule could achieve CESS®-powered success, try STARMAP® for yourself today with our online tool.